医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Experienced Life Sciences Leader Joins IPS as Regional Director to Lead New Australian Office

2024年02月06日 PM11:03
このエントリーをはてなブックマークに追加


 

BLUE BELL, Pa.

IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, proudly announces the appointment of Gordon Nicholson as the Regional Director, ANZ (Australia, New Zealand), to lead IPS’ new Melbourne, Australia office.

Throughout his career, Gordon has successfully led and contributed to a multitude of projects, spanning the design and construction of various life science facilities including Cell and Gene Therapies, from research labs to large-scale manufacturing plants. Before joining IPS, Gordon served in leadership roles across the APAC region from Singapore to Shanghai and Melbourne. Having worked with clients like Sanofi, Bayer, GSK, NovoNordisk and AstraZeneca, he has developed a vast professional network and an in-depth understanding of the region’s dynamics.

“Gordon’s appointment as Regional Director, ANZ allows us to further support our clients in bringing life-changing therapies to patients in Australia and beyond,” said Matthew Shippey, Managing Director, APAC. “The strategic hire of Gordon is the first step of the 2024 regional transformation plan. His commitment to operational efficiency, coupled with years of experience in the APAC market, will be integral to IPS’s ongoing success and expansion in Australia.”

Working closely with APAC leadership, Gordon will have key responsibilities crucial for the company’s success. Gordon will spearhead business development, leveraging his extensive industry network and over three decades of experience to identify strategy opportunities and cultivate valuable partnerships. His expertise will play a pivotal role in driving project and operational excellence, ensuring that IPS continues to deliver client-centered and cutting-edge solutions. Gordon’s leadership will be instrumental in fostering growth within the Australian market, positioning the company as a leading force in the life sciences and pharmaceutical manufacturing sectors.

About IPS

IPS, a Berkshire Hathaway Company, is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides consultancy services, architecture, engineering, project controls, construction management, and compliance services that allow clients to develop and manufacture life-impacting products. Its newest acquisition, Linesight specializes in cost, schedule, risk, program, and project management services in various market sectors, including data centers, life sciences, and high-tech industrial. With the addition of Linesight, IPS has over 3,400 professionals in over 45 offices across 17 countries in the Americas, Europe, and Asia Pacific. For further information, please visit www.ipsdb.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206589347/en/

CONTACT

Dept. of Marketing and Communications

+1.484.344.9234

同じカテゴリーの記事 

  • 卫材启用Medidata Clinical Data Studio推进临床试验效率和患者体验的革新
  • Fujirebio推出研究专用全自动Lumipulse®G GFAP检测试剂盒并进一步强化该公司的神经病学产品阵容
  • Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
  • Pearl、歯科AIで史上最大5,800万ドルの資金調達ラウンドを実施
  • FIGS Announces Date of Second Quarter 2024 Earnings Release, Conference Call and Webcast